ArticleNeuro-oncology2024

A kinome drug screen identifies multi-TKI synergies and ERBB2 signaling as a therapeutic vulnerability in MYC/TYR subgroup atypical teratoid rhabdoid tumors.

Brian Golbourn et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.